Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in HIV infection: a single-arm substudy of a phase 2/3 clinical trial

Frater J., Ewer KJ., Ogbe A., Pace M., Adele S., Adland E., Alagaratnam J., Aley PK., Ali M., Ansari MA., Bara A., Bittaye M., Broadhead S., Brown A., Brown H., Cappuccini F., Cooney E., Dejnirattisai W., Dold C., Fairhead C., Fok H., Folegatti PM., Fowler J., Gibbs C., Goodman AL., Jenkin D., Jones M., Makinson R., Marchevsky NG., Mujadidi YF., Nguyen H., Parolini L., Petersen C., Plested E., Pollock KM., Ramasamy MN., Rhead S., Robinson H., Robinson N., Rongkard P., Ryan F., Serrano S., Tipoe T., Voysey M., Waters A., Zacharopoulou P., Barnes E., Dunachie S., Goulder P., Klenerman P., Screaton GR., Winston A., Hill AVS., Gilbert SC., Pollard AJ., Fidler S., Fox J., Lambe T., Watson MEE., Song R., Cicconi P., Minassian AM., Bibi S., Kerridge S., Singh N., Green CM., Douglas AD., Lawrie AM., Clutterbuck EA.

DOI

10.1016/s2352-3018(21)00103-x

Type

Journal

The Lancet HIV

Publisher

Elsevier BV

Publication Date

08/2021

Volume

8

Pages

e474 - e485

Permalink Original publication